Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis - Test2 - elhamkhani - TriplyDB

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

http://www.wikidata.org/entity/Q22252598

about

Social participation in patients with multiple sclerosis: correlations between disability and economic burden.The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis.Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015 Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice.Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.Multiple sclerosis: basic knowledge and new insights in perioperative management.Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease.Predictors of the 10-year direct costs for treating multiple sclerosis.Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.

P2860

Q33729957-2615DAF5-8080-49EA-B53F-E6A1A4E24705 Q35798769-48A6E731-432D-4B07-9BD2-9632BA8FAC6B Q36240512-4859DE66-62F9-4B47-A35A-928C75B52EFE Q36908003-6AB77AB1-E0E9-472D-92E2-A3FD96CD05C2 Q36953860-105D3C06-87FF-40DD-8F5E-DEDEBDBC0E88 Q38130445-F020910F-13A3-4A54-BC34-5A632E5D9F53 Q38570681-813CFDAF-6AB9-4BA0-831E-BB76E8651CDD Q38693735-88C22ABE-9410-4677-BCEA-E1A09192E5D6 Q38847064-B37AA03C-A063-4686-ADAD-22CBBDB33CAE Q43647433-8C4580F2-DBC9-4B3D-96BB-2330C157D157

P2860

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

http://www.wikidata.org/entity/Q22252598

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@ast

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@en

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@nl

type

label

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@ast

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@en

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@nl

altLabel

Cost-effectiveness of disease-modifying therapies in multiple sclerosis

@en

prefLabel

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@ast

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@en

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@nl

P1433

Q22252598-5593A452-1CA6-434E-B2F1-BBE976A95266

P1476

Q22252598-483A17F7-0AA4-43E8-9013-9A42CBCE3D2B

P2093

Q22252598-E5131CDB-41D0-4263-8D86-B5EDE6C0B770

Q22252598-F787787A-F352-45F1-98DD-C1EBDF3145F3

P2860

Q22252598-057F89E0-492F-42FB-9514-80C3F6117CD5

Q22252598-0D6AA33B-24F3-4D2A-8A93-20A336129A17

Q22252598-0E2FE3AD-EC94-4BB9-8505-B3893D25E944

Q22252598-16D1796B-C6C4-4B36-A646-D9875990BC8A

Q22252598-1862C19A-3B27-407B-927B-7F7416D3E8CB

Q22252598-18FB811F-9057-4FA1-93CF-558548B6CCC0

Q22252598-1B060750-6BC2-4CF9-919B-2CA311483D4E

Q22252598-2B47E694-C585-4647-8A71-DE260834460B

Q22252598-31CFAA73-689A-4524-9C14-610EA1D4F18F

Q22252598-33A7BB16-EDAA-4993-91BB-77D699C052FA

P2888

Q22252598-693197C2-3537-4B6E-BB92-6BC673203000

P304

Q22252598-B92BEC49-A0FC-46AD-B4DD-58F396F63F11

P31

Q22252598-E397C9A1-6866-48D5-A75B-7DBAD55BCC59

P3181

Q22252598-EAD58AB8-1769-4EB5-A9B0-EF78BEA0431C

P356

Q22252598-ED7BDC02-237E-4608-AD6E-C177DF21984C

P407

Q22252598-27E0C115-A635-43B4-A5A1-6FF2321F61CD

P433

Q22252598-80CB5080-99A2-4B04-ACFB-05F69D00698A

P478

Q22252598-282116D9-545E-4EEE-8BE9-8BEC144BEB13

P50

Q22252598-7D543D93-E32E-46B3-90AE-23EF94A67053

Q22252598-D88F382D-B1D1-4F2A-8F53-F8BDFEA9C119

P577

Q22252598-1AACCE02-24C8-4B55-97FC-0731D826B282

P5875

Q22252598-A032C581-D6B2-40F8-B202-E3B7E7C88F53

P6179

Q22252598-FA6A2CD4-5EA2-45D3-92E7-D49C499C82F6

P698

Q22252598-AEA83F5D-1F4B-4313-A1DE-9EF9D7D88E51

P921

Q22252598-63850192-C72E-4EAD-821B-6ED7034E7ABE

P3181

P356

S11910-012-0291-6

P1433

Current Neurology and Neuroscience Reports

P1476

Cost-effectiveness of disease-modifying therapies in multiple sclerosis

@en

P2093

Ali Manouchehrinia

http://www.w3.org/2001/XMLSchema#string

Cris S. Constantinescu

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

P2888

s11910-012-0291-6

P304

592-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1671974

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11910-012-0291-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Cris Constantinescu

Ali Manouchehrinia

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229065142

http://www.w3.org/2001/XMLSchema#string

P6179

1036277151

http://www.w3.org/2001/XMLSchema#string

P698

22782520

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis